NIH R01 · 2025
Abstract Anti-tumor therapies (e.g., anthracyclines, biologic, and immunotherapy) are the standard treatments for most breast cancer patients, and dramatically improve survival rates. However, up to 20% of breast cancer patients treatment with these therapies will develop some form of serious cardiovascular disease (CVD), such as heart failure, myocarditis, or cardiac arrhythmia. Emerging data suggest CVD is now the leading non-malignant cause of death during or after the treatment stage of breast cancer. If clinicians can accurately predict treatment-related cardiotoxicity during the treatment stage or shortly post-treatment, they can then adjust their anti-tumor therapy selection or…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.